Table 2.
Prevalence of HPV for HIV-infected and HIV-uninfected Nigerian MSM who Underwent High-Resolution Anoscopy in Abuja, Nigeria.
| HPV genotype | Total n = 342 n (%) |
HIV-infected n = 204 n (%) |
HIV-uninfected n = 138 n (%) |
P* |
|---|---|---|---|---|
| Multiple HPVs | <0.01 | |||
| 0 | 29 (8.5) | 2 (1.0) | 27 (19.6) | |
| 1 | 38 (11.1) | 14 (6.9) | 24 (17.4) | |
| 2–4 | 168 (49.1) | 101 (49.5) | 67 (48.6) | |
| 5–11 | 107 (31.3) | 87 (42.7) | 20 (14.5) | |
| Multiple High-Risk HPVs | <0.01 | |||
| 0 | 90 (26.3) | 29 (14.2) | 61 (44.2) | |
| 1 | 106 (31.0) | 68 (33.3) | 38 (27.5) | |
| 2–3 | 111 (32.5) | 79 (38.7) | 32 (23.2) | |
| 4–6 | 35 (10.2) | 28 (13.7) | 7 (5.1) | |
| Low-Risk HPV 6 and/or 11 | <0.01 | |||
| No | 198 (57.9) | 103 (50.5) | 95 (68.8) | |
| Yes | 144 (42.1) | 101 (49.5) | 43 (31.2) | |
| High-risk HPVs | ||||
| 16 | 79 (23.1) | 58 (28.4) | 21 (15.2) | <0.01 |
| 18 | 49 (14.3) | 35 (17.2) | 14 (10.1) | 0.07 |
| 31 | 6 (1.8) | 3 (1.5) | 3 (2.2) | 0.69 |
| 33 | 9 (2.6) | 8 (3.9) | 1 (0.7) | 0.09 |
| 35 | 49 (14.3) | 38 (18.6) | 11 (8.0) | <0.01 |
| 39 | 34 (9.9) | 27 (13.2) | 7 (5.1) | 0.01 |
| 45 | 62 (18.1) | 44 (21.6) | 18 (13.0) | 0.05 |
| 51 | 59 (17.3) | 42 (20.6) | 17 (12.3) | 0.05 |
| 52 | 32 (9.4) | 23 (11.3) | 9 (6.5) | 0.14 |
| 56 | 40 (11.7) | 25 (12.3) | 15 (10.9) | 0.70 |
| 58 | 24 (7.0) | 19 (9.3) | 5 (3.6) | 0.05 |
| 59 | 35 (10.2) | 22 (10.9) | 13 (9.4) | 0.68 |
| 68 | 29 (8.5) | 21 (10.3) | 8 (5.8) | 0.14 |
| Low-risk HPVs | ||||
| 6 | 106 (31.0) | 75 (36.8) | 31 (22.5) | <0.01 |
| 11 | 62 (18.1) | 47 (23.0) | 15 (10.9) | <0.01 |
| 42 | 67 (19.6) | 53 (26.0) | 14 (10.1) | <0.01 |
| 54 | 37 (10.8) | 26 (12.8) | 11 (8.0) | 0.16 |
| 67 | 49 (14.3) | 37 (18.1) | 12 (8.7) | 0.01 |
Abbreviations: p, p-value.
*Pearson's Chi-square and Fisher's exact tests. Bold type indicates statistically significant (p < 0.05) differences in HPV prevalence by HIV infection status.